Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Jesse C Nussbaum

Showing results (1-10 of 23) with videos related to

Pageof 3
Sort By:
Cold Spring Harbor Perspectives in Biology|March 30, 2012
Infectious (Non)tolerance--frustrated commensalism gone awry?Jesse C Nussbaum, Richard M Locksley
Eukaryotic Cell|April 13, 2004
Cryptococcus neoformans virulence gene discovery through insertional mutagenesisAlexander Idnurm, Jennifer L Reedy, Jesse C Nussbaum, et al.
Journal of Leukocyte Biology|August 9, 2013
Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lungJennifer K Bando, Jesse C Nussbaum, Hong-Erh Liang, et al.
Clinical Pharmacology in Drug Development|May 5, 2022
Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic CoughPranav Gupta, Azher Hussain, Anthony P Ford, et al.
Current Biology : CB|November 15, 2003
Enzymes that counteract nitrosative stress promote fungal virulenceMarisol de Jesús-Berríos, Limin Liu, Jesse C Nussbaum, et al.
Journal of Clinical Pharmacology|June 3, 2022
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, K Chris Min, et al.
Pharmacology Research & Perspectives|February 2, 2022
Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humansJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
Clinical Pharmacology in Drug Development|June 19, 2021
Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 29, 2023
Transition of care in inborn errors of immunity: Outcomes of a single-center quality improvement initiativeLauren A Sanchez, Monica Tang, Aisha Ahmed, et al.
Cell|December 29, 2014
Activated type 2 innate lymphoid cells regulate beige fat biogenesisMin-Woo Lee, Justin I Odegaard, Lata Mukundan, et al.
Pageof 3

Showing results (1-10 of 23) with videos related to

Sort By:
Pageof 3
Cold Spring Harbor Perspectives in Biology|March 30, 2012
Infectious (Non)tolerance--frustrated commensalism gone awry?Jesse C Nussbaum, Richard M Locksley
Eukaryotic Cell|April 13, 2004
Cryptococcus neoformans virulence gene discovery through insertional mutagenesisAlexander Idnurm, Jennifer L Reedy, Jesse C Nussbaum, et al.
Journal of Leukocyte Biology|August 9, 2013
Type 2 innate lymphoid cells constitutively express arginase-I in the naive and inflamed lungJennifer K Bando, Jesse C Nussbaum, Hong-Erh Liang, et al.
Clinical Pharmacology in Drug Development|May 5, 2022
Clinical Formulation Bridging of Gefapixant, a P2X3-Receptor Antagonist, for the Treatment of Chronic CoughPranav Gupta, Azher Hussain, Anthony P Ford, et al.
Current Biology : CB|November 15, 2003
Enzymes that counteract nitrosative stress promote fungal virulenceMarisol de Jesús-Berríos, Limin Liu, Jesse C Nussbaum, et al.
Journal of Clinical Pharmacology|June 3, 2022
Effects of Renal Impairment on the Pharmacokinetics of Gefapixant, a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, K Chris Min, et al.
Pharmacology Research & Perspectives|February 2, 2022
Characterization of the absorption, metabolism, excretion, and mass balance of gefapixant in humansJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
Clinical Pharmacology in Drug Development|June 19, 2021
Assessment of the Effect of Pyrimethamine, a Potent Inhibitor of Multidrug and Toxin Extrusion Protein 1/2K, on the Pharmacokinetics of Gefapixant (MK-7264), a P2X3 Receptor AntagonistJesse C Nussbaum, Azher Hussain, Bennett Ma, et al.
The Journal of Allergy and Clinical Immunology. in Practice|April 29, 2023
Transition of care in inborn errors of immunity: Outcomes of a single-center quality improvement initiativeLauren A Sanchez, Monica Tang, Aisha Ahmed, et al.
Cell|December 29, 2014
Activated type 2 innate lymphoid cells regulate beige fat biogenesisMin-Woo Lee, Justin I Odegaard, Lata Mukundan, et al.
Pageof 3